|
|
Investment in R&D
CSL is investing in the development of new protein-based medicines for treating serious human diseases as an important avenue for future growth. We have increased our investments significantly over recent years. In 2009/10 we invested A$317 million in our R&D programs and this will continue to increase in 2010/11. We endeavor to make balanced investment in life cycle management and market development of existing products resulting in short to mid term growth, as well as strategic investment in longer term, higher risk and high opportunity new product development activities in areas aligned with our core capabilities and commercial strengths. R&D Investment Growth
|